Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia

摘要: Abstract Familial hypercholesterolemia (FH) is characterized by severe and premature coronary heart disease (CHD). The lower the plasma cholesterol level, more likely it that CHD can be prevented or retarded; aggressive cholesterol-lowering therapies may indicated for FH patients with CHD. This study describes long-term (6 years) safety efficacy of intensive low-density lipoprotein (LDL) apheresis in heterozygous One hundred thirty documented angiography had been treated drug therapy alone (n = 87) LDL combined drugs 43). Serum lipid levels outcomes each treatment group were compared after approximately 6 years. Both groups significant reductions serum cholesterol, high density levels. significantly reduced from 7.42 ± 1.73 to 3.13 0.80 mmol/L (58%) taking therapy, 6.03 1.32 4.32 1.53 (28%). With Kaplan-Meier analyses events including nonfatal myocardial infarction, percutaneous transluminal angioplasty, artery bypass grafting, death CHD, rate total was 72% LDL-apheresis (10%) than (36%) (p 0.0088). It concluded effective as heterozygotes, become choice types FH.